Scholars Central

Conference abstract

NSCLC vaccines: Past, present and future

Authors: Jhanelle Gray

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Immune checkpoint inhibitors have paved the way for immunotherapy as a therapeutic option for NSCLC through their demonstration that harnessing a patient’s immune system can lead to long-lasting effects through the ultimate generation of immune memory. Vaccines too have had success in cancer (e.g., prostate cancer) and serve as proof of principle. In NSCLC, various vaccines have been explored. In the Phase III STOP trial, no OS benefit was shown in stage III/IV NSCLC patients randomized to belagenpumatucel-L (Lucanix), an allogeneic vaccine of TGF-Beta2 antisense versus placebo. Still, those with prior radiation therapy or SQCLC histology showed marked improvements in OS. BLP-25 (Tecemotide; Stimuvax), a liposomal MUC1 peptide vaccine, was evaluated in the START trial but OS was not improved in stage III NSCLC patients versus placebo, although a benefit was shown in those previously treated with concurrent versus sequential chemoradiation therapy. The MAGE-A3 protein vaccine was evaluated in early-stage NSCLC, but DFS was not improved versus placebo (MAGRIT trial). Although these trials established safety in administering vaccines to NSCLC patients, improvements are needed. Vaccine studies in NSCLC patients now include the ongoing Phase I/II randomized trial to evaluate the GM. CD40L (Arm A) versus GM.CD40L.CCL21 (Arm B) vaccine in lung adenocarcinoma patients. As of May 2015, Phase I enrolled 3, while Arms A and B enrolled 36/33 patients (median age: 69.5/69 years, females: 50.0%/52.7%, and PS1: 67%/64%), with both vaccines being tolerable. Moving forward, NSCLC vaccines hold promise, and trials to explore combination strategies with immune checkpoint inhibitors are underway.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Stem Cell Research & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Stem Cell Research & Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Jhanelle Gray”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels